FDA Advisory Panel Questions Data Reliability for Amgen’s Lung Cancer Drug Lumakras

FDA Advisory Panel Questions Data Reliability for Amgen’s Lung Cancer Drug Lumakras

Advisers to the U.S. Food and Drug Administration (FDA) have raised concerns about the reliability of data from a late-stage…

Read More »